Brief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
24/05/2023 22:35
May 24 (Reuters) - AstraZeneca PLC AZN.L :
* TCR2 THERAPEUTICS INC: ON MAY 23 ENTERED INTO AN
ASSIGNMENT OF
LEASE AGREEMENT WITH ASTRAZENECA - SEC FILING
* TCR2 THERAPEUTICS: EFFECTIVE DATE OF LEASE ASSIGNMENT WILL
BE
JUNE 1 AT WHICH TIME ASTRAZENECA WILL ASSUME CO'S OBLIGATIONS
UNDER ROCKVILLE LEASE
* TCR2 THERAPEUTICS INC: AGREED TO CONVEY TO ASTRAZENECA
CERTAIN
EQUIPMENT, PAY $0.9 MILLION IN CASH TO DEFRAY ADDITIONAL
EQUIPMENT AND BUILD-OUT COSTS
Source text for Eikon: ID:
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview